COVID-19 Vaccine Recommendations Fall 2025-2026 Season

FDA Approval Vaccines 2025-2026			
Brand	Dose	TIMING	INDICATION (Based on FDA approval recommendations)
Moderna (mNexspike)®	0.2 mL IM	 ADMINISTER 3 MONTHS AFTER LAST DOSE OF COVID-19 VACCINE 	 65YRS AND > 12 YEARS-64 YEARS OF AGE AT HIGH RISK FOR SEVERE COVID-19*
Moderna (Spikevax)®	 0.25ml IM (6mos-11yrs of age) 0.5ml IM (12 yrs age and older) 	 Individuals 6-23 months of age timing based on number of previous doses (see MFG website) 2-11 yrs of age, single dose, 0.25ml (≥ 2 months from last dose) ≥12 years of age, single dose 0.5ml (≥ 2 months from last dose) 	 65YRS AND > 6months -64 YEARS OF AGE AT HIGH RISK FOR SEVERE COVID-19* Note PA Law only allows pharmacists to administer 5 years and older.
Pfizer (Comirnaty)®	 5 years through 11 years of age: a single dose is 0.3 mL IM (supplied in vials with blue caps and labeled with blue borders.) 12 years of age and older: a single dose is 0.3 mL IM (supplied in prefilled syringes labeled with gray borders.) 	ADMINISTER 3 MONTHS AFTER LAST DOSE OF COVID-19 VACCINE	 65YRS AND > 5 YEARS-64 YEARS OF AGE AT HIGH RISK FOR SEVERE COVID-19*
Novavax (Nuvaxovid)®	0.5ml for all ages	IM ADMINISTER 2 MONTHS AFTER LAST DOSE OF COVID-19 VACCINE	 65YRS AND > 12 YEARS-64 YEARS OF AGE AT HIGH RISK FOR SEVERE COVID-19*

^{*}Immunocompromised includes the following: active cancer treatment, organ transplant and receiving immunosuppressive therapy, stem cell transplant within 2 years or taking immunosuppressive therapy, moderate to severe primary immunodeficiency (DiGeorge syndrome, Wiskott-Aldrich syndrome), advanced or untreated HIV, active treatment with high-dose corticosteroids, active treatment with medications that may suppress the immune system

^{*}Underlying medical conditions examples (ex: cancer, chronic kidney disease, chronic liver disease, chronic lung diseases, diabetes, heart conditions, obesity, pregnancy, sickle cell disease, current/former smoker, transplant recipient, previous stroke)

Summary of Newly approved sources of Authority Recommendations for PA Pharmacists**				
	Recommendation	Additional Info and Website Link:		
U.S. Food & Drug Administration (FDA)	See Table 1 above	Healthcare Professional Website Links: 1. Moderna (mNexspike)® 2. Moderna (Spikevax)® 3. Pfizer (Comirnaty)® 4. Novavax (Nuvaxovid)®		
American Academy of Family Physicians (AAFP)	 6 months of age and older receive Covid-19 vaccine regardless of prior vaccine status Emphasized High-Risk Groups receive the vaccine (Older adults, individuals with underlying health conditions*, pregnant women and those who are immunocompromised) 	 Covid-19 vaccines can be administered at the same time as other vaccines, including flu vaccine. Website: Clinical Guidance: Discussing COVID-19 Vaccinations With Your Patients Fam Pract Manag. 2025;32(4):49-52 		
American Academy of Pediatrics (AAP)	 Everyone age 6-23 months Age 2-18 years in the following risk groups: persons at high risk of severe Covid-19*, residents of long-term care facilities or other congregate settings, persons who have never been vaccinated against Covid-19, persons who household contacts are at high risk for severe Covid-19 	 Refer to age specific dosing guidelines of vaccines based on age and history of Covid 19 vaccine Website: https://downloads.aap.org/AAP/PDF/AAP-Immunization-Schedule.pdf?gl=1*1pbpja*ga*MjEyMTI10DMyNi4xNzU3Mjg0NTU3*ga_FD9D3XZVQQ*czE3NTcyODQ1NTYkbzEkZzEkdDE3NTcyODQ1NzgkajM4JGwwJGgw 		
American College of Obstetricians and Gynecologists (ACOG)	Pregnant (Vaccinated in any trimester)Lactating Individuals	Website: https://www.acog.org/programs/immunization-infectious-disease-public-health/tools-and-resources/covid-19-vaccines-and-pregnancy-conversation-guide-for-clinicians		

^{**}On Wednesday, September 3, 2025, the Pennsylvania State Board of Pharmacy unanimously approved the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) as competent authorities pursuant to 49 Pa. Code 27.403(e). Effective immediately, this approval allows pharmacists or pharmacy interns who have the authority to administer immunizations to continue to do so in accordance with (i) the treatment guidelines of a physician and (ii) the guidelines established by ACOG, AAP, or AAFP. Additionally, the Board unanimously approved the Food and Drug Administration (FDA) as a competent authority pursuant to 49 Pa. Code 27.403(e) as it relates to COVID-19 immunizations. Effective immediately, this approval allows pharmacists or pharmacy interns who have the authority to administer immunizations to administer COVID-19 immunizations in accordance with (i) the treatment guidelines of a physician and (ii) the guidelines established by the FDA. The approval of the above authorities is an option for providers *in addition* to the guidelines established by the Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices.

Additional Notes:

- The PREP Act remains in effect, so existing allowances for vaccine administration still apply.
 - Pharmacies should update intake forms to include questions about pregnancy, lactation, and whether patients under 65 have conditions that warrant vaccination.
- Standing orders must be reviewed and updated to align with current vaccine indications, in collaboration with the supervising physician.
- Pharmacies should verify coverage with insurance plans before billing.